cancerous types News
-
Ildong’s affiliate gets nod for phase 1b/2a trial of new cancer drug in Korea
Idience Co., a drug discovery and development company affiliated to South Korea’s Ildong Holdings, announced on Monday it has received approval of a phase 1b/2a trial of its investigational cancer drug IDX-1197 from the Ministry of Food and Drug Safety. The company said the new clinical study will evaluate the drug’s safety and efficacy profile in more cancer types than the phase 1a ...
-
IONIQ Presents Lung Cancer Trial Results at ATS 2022
IONIQ Sciences is proud of our team members who presented our latest lung cancer clinical trial results in a poster today at the American Thoracic Society meeting in San Francisco, CA. This was a great honor to highlight our growing bioimpedance clinical evidence that continues to demonstrate the possibility of a non-invasive, low-cost, early-stage lung cancer diagnosis. Furthermore, the ...
-
IONIQ Receives Three Awards including ‘Best Medical Technology Company 2022’
IONIQ Sciences is humbled to be recognized with three separate awards from ‘Global 100‘ especially during ‘Lung Cancer Hope Month.’ These three awards and earlier designation by the US FDA as a ‘Breakthrough Device‘ is further validation of our growing clinical evidence library from seven trials at 24 sites with 1.2K subjects and more than 20M data points. ...
-
Aesther Healthcare (AEHA) Announces $75M Share Purchase Agreement for Ocean Biomedical Deal
Aesther Healthcare (NASDAQ:AEHA) announced this morning that it has inked a common stock purchase agreement with White Lion Capital that will provide up to $75 million to its combination target Ocean Biomedical. Following close, Ocean may direct White Lion to purchase shares in the company worth up to $2 million or 67% of the five-day average daily trading volume. White Lion previously signed an ...
-
Cancer Therapy Advisor Named Top Breast Cancer App
Cancer Therapy Advisor (CTA), a leading source of cancer research news and drug information, has been named one of the top breast cancer apps of 2020 by Healthline for the fifth year in a row. The CTA app is designed for oncology professionals and compiles oncology research news, practical cancer treatment regimens, feature articles and expert interviews, slideshows, case studies, and drug ...
-
4D Path Makes Continued Investments in Robust IT Infrastructure for Novel Precision Oncology Platform
4D Path applies universal physics, biology and mathematical principles to identify tumor-specific phenotypic and genotypic fingerprints. Its system runs on modern cloud components that enable dynamic scaling and batch processing, allowing 4D to optimize run times and deliver rapid results. Utilizing Microsoft Azure's cloud technology, 4D Path has built stable and secure ...
By 4D Path Inc.
-
GRAIL Statement on President Biden’s Bold Initiative to Reignite the Cancer Moonshot
“We applaud President Biden for reigniting the Cancer Moonshot and highlighting the critical role of early detection in achieving the ambitious, but attainable, goal of reducing the cancer death rate by at least 50 percent in the next 25 years. Improving quality of life for patients and survivors, while addressing inequities in access to cancer screening, diagnostics and treatment is a ...
By Grail, Inc.
-
Creative BioMart Provides a Wide Range of Centromere Proteins for Research Use
Creative BioMart, a world leading biotech company specialized in providing quality protein products and services to customers all over the world now provides a wide selection of centromere proteins for cancer research. Centromeres are specialized DNA sequences in chromosomes, which hold two daughter chromatids together. Centromeres represent a contractile region of the chromosome in which two ...
-
Lightpoint Medical to Present Positive Clinical Trial Data for SENSEI Miniature Gamma Probe in Prostate Cancer Surgery
Lightpoint Medical, a leading medical device company developing and marketing innovative technologies for intra-operative cancer detection, announced clinical trial results today to support the use of the company's miniature surgical gamma probe, SENSEI®, in prostate sentinel lymph node detection. The interim results from the multi-center clinical trial, which involves cancer centers at ...
-
Biosceptre welcomes Tuspark S & T into its Series A fund raising round
Biosceptre has received over £8M into its’ series A raise which will be used to resource the next stage of the companies’ development; progression into the clinic of Biosceptre’s first systemic products against novel oncology target nfP2X7. Biosceptre will close the series A on the 21st December, 2017. The major portion of the raise received to date was led by Tuspark ...
-
USMI Developing the First Surgical Robot for Cancer Surgery
US Medical Innovations, LLC (USMI) announced today that it is developing the first robotic delivery system used for cancer surgery. The new Canady Surgical System (CSS) is a space-efficient, cost-effective, stand-alone solution for Robotic Assisted Surgery during open, laparoscopic/mini-invasive, endoscopic, thoracoscopic and trans-oral surgical procedures. Features of the new Canady Surgical ...
-
Aptorum Group Granted The First Patent for its SACT-1 Repurposed Drug For Treatment of Various Cancer Including but Not Limited to Neuroblastoma
NEW YORK & LONDON & PARIS--(BUSINESS WIRE)--Jan. 18, 2022-- Regulatory News: Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) (“Aptorum Group” or “Aptorum”), a clinical-stage biopharmaceutical company, is pleased to announce that the US Patent and Trademark Office has granted the first patent regarding Aptorum’s SACT-1 repurposed drug for the ...
-
GRAIL Announces Partnership with Alignment Health Plan as First Medicare Advantage Plan to Offer Galleri® Multi-Cancer Early Detection Blood Test
GRAIL, LLC, a healthcare company whose mission is to detect cancer early when it can be cured, announced today a partnership with Alignment Health Plan, a national Medicare Advantage health plan from Alignment Healthcare (NASDAQ: ALHC), to provide its Medicare Advantage members access to Galleri®, GRAIL’s groundbreaking multi-cancer early detection blood test. Based in Orange, ...
By Grail, Inc.
-
LISCure Biosciences Announces Research Collaboration with The Scripps Research Institute for Immuno-Oncology
LISCure Biosciences ("LISCure") announced that it had reached an agreement with The Scripps Research Institute ("Scripps Research") to collaboratively research on bacteria-mediated immuno-oncology candidates against multiple cancer types. Scripps Research is the top nonprofit scientific institute in the US for producing high-quality research based on discoveries published in leading scientific ...
-
No time to lose in protecting your workers from occupational cancer risks
Latest Met Office records show that April 2015 was the sunniest on record since Met Office records began in 1929 – with the UK clocking up an average 212 hours of sunshine during the month. But the sun does have a downside. In Britain, five people a day are diagnosed with a work–related skin cancer. Sixty people every year die from skin cancer caused by working in the sun. IOSH has ...
-
CytomX Therapeutics to Present at Jefferies 2022 Global Healthcare Conference
CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated oncology therapeutics, today announced that Sean McCarthy, D.Phil., chief executive officer and chairman, will present at the Jefferies Healthcare Conference on Wednesday, June 8, 2022 at 2:00 p.m. ET. A live webcast of the presentation will be available on the Events and Presentations page of ...
-
PixCell Medical Opens United States Subsidiary to Support Commercial Growth
PixCell Medical, innovator of rapid diagnostic solutions at the point-of-care, today announced the opening of a United States subsidiary in the Denver metropolitan area. The new office will increase logistical and commercial support for PixCell's U.S. clients and will handle order fulfilment across the country, as well as provide additional clinical and technical support to customers. "Opening a ...
-
Closing of financing round and strengthening of development team paves the way for T3 Pharma to enter the clinic
T3 Pharmaceuticals AG (T3), a Basel (Switzerland)-based company focusing on immuno-oncology, closes its second financing round of over 12M CHF with existing investors joined by «Boehringer Ingelheim Venture Fund» (BIVF) and «Reference Capital SA». To progress into the clinical phase, T3 appoints Claire Barton as Chief Medical Officer, strengthens its development team and ...
-
Aptorum Group Announces the Launch of its Oncology and Autoimmune Discovery and Development Platform Targeting Unmet Mutations and Novel Biomarkers
NEW YORK & LONDON & PARIS--(BUSINESS WIRE)--Jan. 10, 2022-- Regulatory News: Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) (“Aptorum Group” or “Aptorum”), a clinical-stage biopharmaceutical company, announces the launch of its oncology and autoimmune discovery and development platform with an initial focus on indications including, but not limited to, ...
-
Calviri Demonstrates That RNA Processing Errors Are a Rich Source of Tumor Neoantigens for Cancer Vaccines
Calviri, Inc., a biotech startup spun out of Arizona State University Biodesign Institute, focused on prevention and treatment of cancer, announced results that demonstrate the potential of a prophylactic vaccine against cancer. The study of RNA processing errors in tumors highlighted that a large number of frameshift neoantigens are produced. This new class of neoantigens are shown to be ...
By Calviri
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you